Endometrial Receptivity Testing: Can ERA Really Find the Implantation Window?

What ERA tries to measure

ERA usually requires an endometrial biopsy in a mock cycle. The laboratory measures gene-expression signals associated with receptivity and classifies the sample as pre-receptive, receptive or post-receptive. The proposed clinical action is a personalized embryo-transfer window.

The method therefore sits between three variables: embryo quality, endometrial status and progesterone exposure time. A result can sound precise, but precision in measurement does not automatically mean better live-birth outcomes.

The hard outcome is live birth

Randomized evidence published in JAMA did not show a meaningful live-birth benefit from routine receptivity testing in good-prognosis IVF patients. Later evidence reviews and guideline discussions have remained cautious.

NICE, ESHRE and HFEA have all taken conservative positions on many IVF add-ons when evidence is insufficient, mixed or not clearly linked to live birth. That does not mean the biology is fake; it means the clinical promise has not been proven for routine use.

Four claims that need caution

Claim one: "the test finds your exact implantation window." In reality, the biopsy is taken in a model cycle and interpreted by an algorithm. Claim two: "it explains every failed transfer." Implantation failure can involve embryo aneuploidy, uterine pathology, inflammation, thrombosis, technique and chance. Claim three: "it improves success for everyone." That is not supported. Claim four: "if you do not test, you waste embryos." This is fear-based marketing.

Who might discuss it

A cautious discussion may be reasonable after repeated implantation failure when embryo quality, uterine cavity, transfer technique, endocrine timing and other major factors have already been reviewed. Even then, the patient should understand cost, biopsy discomfort, cycle delay and uncertainty.

Routine use for first transfer, good-prognosis patients or as a general "success-rate booster" should be avoided.

Eight questions before paying for the test

Ask whether the clinic expects a live-birth benefit in your specific scenario, what evidence supports that expectation, whether cheaper causes of failure have been reviewed, whether the biopsy cycle matches the transfer cycle, what happens if the result is displaced, how much delay and cost will be added, and whether the recommendation is optional or being used as a sales condition.